Search research articles
Contact Us
Filters
Showing results (21-30 of 24) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 24 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2019
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
JAMA
|
September 28, 2019
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
Elizabeth Alexander, Lisa Goldberg, Anita F Das, et al.
Journal of Global Antimicrobial Resistance
|
November 17, 2021
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin
Susanne Paukner, Lisa Goldberg, Elizabeth Alexander, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 28, 2022
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials
Jessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 24) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 24 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 19, 2019
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M File, Lisa Goldberg, Anita Das, et al.
JAMA
|
September 28, 2019
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
Elizabeth Alexander, Lisa Goldberg, Anita F Das, et al.
Journal of Global Antimicrobial Resistance
|
November 17, 2021
Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin
Susanne Paukner, Lisa Goldberg, Elizabeth Alexander, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 28, 2022
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials
Jessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.
Page
of 3